Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ASTX030 + Azacitidine + Cedazuridine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ASTX030 | ASTX 030|ASTX-030|AZA/CDZ Combination|Cedazuridine + Azacitidine | ASTX030 is a combination of azacitidine and cedazuridine, which may lead to inhibition of cell proliferation of tumor cells (Blood (2019) 134 (Supplement_1): 1376). | ||
Azacitidine | Vidaza | azacytidine|CC-486|5-azacytidine|5-AC|U-18496|Onureg | DNMT inhibitor (Pan) 5 | Vidaza (azacitidine) is a cytidine analog that incorporates into DNA and RNA and binds to DNA methyltransferases (DNMTs), resulting in DNMT degradation and decreased DNA methylation, and leading to increased tumor cell death (PMID: 28159832, PMID: 28067760). Vidaza (azacitidine) is FDA-approved for use in patients with some subtypes of myelodysplastic syndrome and Onureg (azacitidine) is FDA approved for use in continued treatment of acute myeloid leukemia(FDA.gov). |
Cedazuridine |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04256317 | Phase III | ASTX030 ASTX030 + Azacitidine ASTX030 + Azacitidine + Cedazuridine | A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML | Active, not recruiting | USA | CAN | 0 |